Can you take secukinumab during pregnancy?
Secukinumab is an IL-17A inhibitor. The provided information does not include pregnancy-specific study results, dosing guidance, or regulatory labeling for use in pregnancy, so a clinician should decide case-by-case based on disease severity and available safety data.
What do people usually ask about secukinumab in early pregnancy (first trimester)?
Patients commonly want to know whether exposure early in pregnancy increases the risk of miscarriage or birth defects, and whether stopping secukinumab before conception changes that risk. The provided information here does not include human pregnancy outcome data or teratology findings, so those questions need to be answered using the product’s prescribing information and any pregnancy registry or post-marketing data your clinician can access.
Does secukinumab affect fetal development or placental transfer?
The key practical question is whether monoclonal antibodies like secukinumab cross the placenta, which typically becomes more relevant later in pregnancy for many biologics. However, the provided information does not specify placental transfer timing for secukinumab or animal developmental toxicity results.
What do guidelines tend to recommend for biologics like secukinumab in pregnancy?
Clinicians often balance two risks: medication exposure versus uncontrolled maternal inflammatory disease (which itself can lead to pregnancy complications). Without the provided pregnancy guidance or label text for secukinumab, it’s not possible to state a specific recommendation here.
What should patients do if they become pregnant while on secukinumab?
A common next step is to contact the prescribing specialist promptly to review:
- gestational age,
- current disease control,
- prior flare history if the drug is held,
- and alternatives that may have more pregnancy safety data.
The provided information does not include a protocol for stopping or switching secukinumab during pregnancy.
Can you breastfeed while taking secukinumab?
Breastfeeding safety depends on whether the drug is expected to enter breast milk and how much is absorbed by an infant. The provided information does not include milk transfer or breastfeeding recommendations for secukinumab.
Are there pregnancy registries or safety databases for secukinumab?
Many biologics have post-marketing pregnancy surveillance or registries. The provided information does not name any secukinumab registry or summarize registry findings, so your clinician or pharmacist would need to check the latest registry availability and data.
How does secukinumab compare with other psoriasis/arthritis biologics in pregnancy?
Patients often compare secukinumab with TNF inhibitors and other biologics because the amount and duration of pregnancy safety data varies by drug. The provided information does not include comparative pregnancy safety details for secukinumab.
---
Sources are not provided in the prompt, so I can’t cite specific pregnancy findings or labeling. If you share whether this is for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, or another condition (and which country you’re in), I can tailor the answer to the most relevant prescribing information and safety resources.